Javier Ampuero, MD, PhD - Making MASH a Priority in Our Gastroenterology Practices: Why We Should and How We Can

For the complete activity, including supporting material, please visit https://www.peervoice.com/PXK860. Presented by Javier Ampuero, MD, PhD and Meena B. Bansal, MD, FAASLD. Learning Objectives: Explain the rationale for prompt identification and active management of individuals with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, based on the increased risk of adverse liver outcomes associated with progression of fibrosis; Evaluate the impact of novel MASH-targeted therapies, such as THR-β agonists, on the underlying pathophysiology and progression of the disease; Identify proactive and systematic approaches that can be practically implemented in gastroenterology practices for the assessment of fibrosis risk in individuals with specific characteristics and comorbid conditions.

Listen